



Correlation between Glycated Hemoglobin and Serum Lipids in Type 2 Diabetics in Eastern Libya

Nura Mohammed Naseb¹, Ramesh Naidu Yedla², Khalid Saleh Gharib³, Jagannadha Rao Peela^{4*}, S. Shakila⁴, Abdul Rehman Said⁴, Laxmi Teja Peela⁵, Sobha Devi Kolla⁶, Sainath Jagannath Doiphode⁷, Anuradha Argi⁸, V. Laxmi Kalpana⁸, Avinash Rawal⁹ and Soe Naung¹⁰

¹Department of Biochemistry, Faculty of Medicine, University of Benghazi, Benghazi, Libya.

²Department of Medicine, Rangaraya Medical College, Kakinada, AP, India.

³Department of Biochemistry, Faculty of Medicine, Omar Al-Muhkthar University, Al-Baida, Libya.

⁴Department of Biochemistry, Faculty of Medicine, Quest International University Perak, Ipoh, Malaysia.

⁵Great Eastern Medical School, Srikakulam, India.

⁶Department of Biochemistry, Rangaraya Medical College, Kakinada, India.

⁷Department of Pharmacology, Guardian College of Dental Sciences and Research Centre, Ambarnath, Thane, Maharashtra, India.

⁸Department of Human Genetics, Andhra University, Visakhapatnam, India.

⁹Department of Biochemistry, Faculty of Medicine, St Mathews Medical University, Grand Cayman, Cayman Islands.

¹⁰Community Medicine, Faculty of Medicine, Quest International University, Perak, 30250 Ipoh, Malaysia.

Authors' contributions

This work was carried out in collaboration between all authors. Author JRP designed the study, author SN performed the statistical analysis, authors NMN and KSG wrote the protocol, and wrote the first draft of the manuscript and managed literature searches. Authors LTP, VLK and AA helped in writing and formatting. Authors SS, SJD, SDK, ARS and RNY managed the analyses of the study and literature searches. Author AR helped reviewing process. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/BJMMR/2016/18537

Editor(s):

(1) Mahin Khatami, National Cancer Institute (ret.), The national Institutes of Health, Bethesda, MD, USA.

(2) Jia Xu, University of Texas-M.D. Anderson Cancer Center, Houston, USA.

Reviewers:

(1) Iskra Ventseslavova Sainova, Institute of Experimental Morphology, Bulgaria.

(2) Masahiro Ohira, Toho University Medical Center, Japan.

(3) Ahmed Mohamed Zahran, Menoufia University, Egypt.

(4) Alexander Berezin, Medical University, Zaporozhye, Ukraine.

(5) Anonymous, National Nutrition Institute, Cairo, Egypt.

(6) Marco Matteo Ciccone, University of Bari, Italy.

(7) Anonymous, USA.

(8) Ayşenur Yeğin, Antalya Research And Educational Hospital, Turkey.

Complete Peer review History: <http://sciencedomain.org/review-history/11608>

ABSTRACT

Introduction: Type 2 diabetes is an increasingly common metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Diabetes mellitus is frequently associated with dyslipidemia and an increased percentage of glycosylated hemoglobin. Patients with type 2 diabetes mellitus are at increased risk for cardiovascular complications.

Objective: To assess the relationship between glycemic control (as reflected by glycosylated hemoglobin; HbA1c) and serum lipid profile in type 2 diabetic patients.

Materials and Methods: A total of 60 patients were selected from those attending Diabetes Mellitus Clinic, Seventeenth of February Teaching Hospital, Al- Baida as outpatients. The subjects were divided into 3 groups such as group I as the control group, group II as the diabetic group with all related complications excluded and group III as those with type 2 DM with at least cardiovascular event in the last two years considered as cardiovascular complication of DM. Blood samples were collected from all the subjects and tested for glucose level, glycosylated hemoglobin, total cholesterol, triglycerides and HDL cholesterol using authenticated reagents kits on an auto analyzer. LDL cholesterol was calculated using Friedwald's formula.

Results: The levels of glycosylated hemoglobin ($p < 0.0001$), fasting glucose level ($p < 0.0001$) and triglycerides ($p < 0.0001$), were significantly raised and HDL cholesterol ($p < 0.0001$) is found to have significantly decreased in diabetic patients with or without cardiovascular complications. In those patients with diabetic complications, total cholesterol and low density lipoprotein cholesterol were significantly raised and high density lipoprotein cholesterol significantly decreased when compared to control subjects.

Conclusion: The findings of the study showed significant positive correlation between glycosylated hemoglobin with the levels of total cholesterol, triacylglycerol, and low density lipoprotein cholesterol in both control and diabetic groups with or without complications. Glycosylated hemoglobin level was significant and positively correlated with total cholesterol and triglycerides in type 2 DM.

Keywords: Glycosylated hemoglobin; type 2 DM; serum lipids.

1. INTRODUCTION

Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from a defect in insulin secretion, insulin action or both [1,2]. Glycosylated hemoglobin is an objective measure of glycemic control, which reflects average plasma glucose over the previous eight to twelve weeks. Type 2 DM was previously referred to as non-insulin dependent diabetes or adult-onset diabetes. It consists of an array of dysfunctions characterized by hyperglycemia resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion [3-5]. Dyslipidemia is another more prominent in biochemical finding in type-2 diabetes and in poorly controlled diabetes there is impaired low density lipoprotein (LDL) catabolism which leads to its elevated concentration in blood [6].

Prevalence of diabetes mellitus is a global problem and Libya is no exception to this problem mainly due to the raised incidence of metabolic syndrome, genetic predisposition and dietary habits. Complications of diabetes includes neuropathy, nephropathy, retinopathy and other vascular complications particularly atherosclerosis.

The aim of the current prospective study was to evaluate correlation between glycosylated hemoglobin and serum lipids in type 2 diabetics in eastern Libya.

2. MATERIALS AND METHODS

In the present study, 60 subjects of either sex in the age group between 30 to 75 years were selected. The details of the age, body weight and body mass index (BMI) were given in Table 1. The study was carried out on outpatients from the department of Diabetes Mellitus Clinic,

Seventeenth of February Teaching Hospital, Al- Baida. This study was approved by ethics committee of Al Mukhtar University, Al Baida, Libya in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The subjects were grouped based on cardiovascular complications such as coronary heart disease as follows:

| Study groups | |
|--------------|---|
| Group I | Control group with twenty subjects from similar age group and physical characteristics. . 18 males and 2 females |
| Group II | Consists of twenty patients with diabetes with no other diabetes associated complications. 11 males and 9 females |
| Group III | Consists of twenty patients with diabetes with known history of coronary heart disease in the last two years. 11 males and 9 females. |

Blood samples from all the subjects were collected and analyzed for Glycated Hemoglobin, Fasting plasma glucose and lipid profile. All laboratory work was carried out at the labs of Biochemistry Department, Omar Al-Mukhtar Faculty of Medicine and Clinical Laboratory at Seventeenth of February Teaching Hospital, Al-Baida. The blood samples were collected into EDTA tubes for determination of HbA1c; in fluoride oxalate tubes for fasting glucose (FG) and serum separator tube for lipid profile measurement.

Table 1. Mean age, body weight and BMI

| Groups | Age | Body weight | BMI |
|-----------|--------------|-------------|----------|
| Group I | 46.05±11.408 | 65±4.576 | 21.7±2.5 |
| Group II | 57.65±7.915 | 66±7.765 | 22.7±2.8 |
| Group III | 61.5±6.030 | 69±6.435 | 23.8±2.0 |

Blood glucose was estimated by enzymatic colorimetric method [7]. Glycated hemoglobin was estimated by chromatographic spectrometric Ion exchange method [8]. Cholesterol was measured by enzymatic method [9-12].

LDL cholesterol was calculated using Friedwald's formula ($LDL = TC - HDL - TGS/5$) [13] Lipid risk ratio was calculated by the ratio between total cholesterol and HDL cholesterol. Correlation test was done by pearson method using microsoft excel sheet.

Statistical analysis was done by using SPSS software and calculated post hoc sample size. We used Mann Whitney U test for calculating p-values. Correlation was done by pearson method in Microsoft excel sheet.

3. RESULTS

The fasting glucose and glycated hemoglobin levels of the study groups are presented in Tables 2 and 3, respectively. The p-value showed a significant difference in fasting plasma glucose ($p < 0.001$), and in hemoglobin A1c ($p < 0.001$) in control (group I) compared with other two study groups II and III. There was no significant difference ($p > 0.05$) between group II and group III.

The results of lipid profile are presented in Table 4. It is revealed that serum total cholesterol, serum LDL-C, serum triacylglycerides and lipid risk ratio were found to be in the higher range in patients with diabetic complication (group III) in comparison to control subjects (group I). Serum total cholesterol, serum LDL, serum triacylglycerides, lipid risk ratio were raised in patients with diabetic (group II) in comparison to control subjects (group I).

The p-value for all the parameters showed that there was significant difference in the serum total cholesterol ($p < 0.001$), serum LDL cholesterol ($p < 0.05$), serum triacylglyceride levels ($p < 0.001$) and serum lipids risk ratio ($p < 0.001$) between group I and group III. There was significant difference in the serum LDL cholesterol ($p < 0.05$), serum lipids risk ratio ($p < 0.001$) between group II and group III. However, there was no significant difference in the serum total cholesterol ($p > 0.05$), serum triacylglycerides ($p > 0.05$) and serum lipids risk ratio ($p < 0.001$) between group (II) and group (III).

There is a positive correlation between Glycated hemoglobin and Total Cholesterol, LDL cholesterol, Triglycerides and negative correlation to HDL cholesterol but not significant may be due to small sample size in each category. The results of correlation between glycated hemoglobin and other lipids were mentioned in Table 5.

4. DISCUSSION

The characteristic features of diabetic dyslipidemia are a high plasma triglyceride

Table 2. Fasting plasma glucose (mg/dl) in control and two other studied groups (Number = 20 each)

| Groups | Control (group I) | Group II (group I Vs. Group II) | Group III (group I Vs. Group III) |
|--------|-------------------|------------------------------------|--------------------------------------|
| Range | 64 – 110 | 86 – 224 | 124 - 377 |
| Mean | 90.7 | 158.95** | 191.85** |
| S.D. | ± 13.85 | ± 39.99 | ± 56.053 |

** $p < 0.001$

Table 3. HbA1c% in control and two other study groups

| Groups | Control (group I) | Group II (group I Vs. Group II) | Group III (group I Vs. Group III) |
|--------|-------------------|------------------------------------|--------------------------------------|
| Range | 4.2 – 6.0% | 6.3 – 15.8% | 6.6 – 13% |
| Mean | 5.64 | 9.23** | 8.86** |
| S.D. | ± 1.66 | ± 2.265 | ± 1.62 |

** $p < 0.001$

Table 4. Serum cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol levels in control and two other studied groups

| Parameters | Control (group I) | Group II (group I vs. group II) | Group III (group I vs. group III) |
|--------------------------|-------------------|------------------------------------|--------------------------------------|
| | mean±S.D | mean±S.D | mean±S.D |
| Total cholesterol(mg/dL) | 124.65±29.16 | 150.20±52.62** | 171.2±47.246** |
| LDL cholesterol(mg/dL) | 54.82±28.80 | 107.97±46.17* | 109.55±46.40* |
| Triglycerides (mg/dL) | 136.40±39.83 | 163.60±82.25** | 162.70±59.54** |
| HDL cholesterol (mg/dL) | 46.15±18.58 | 35.65±8.66* | 28.10±5.37** |
| Lipids risk ratio | 2.70±1.611 | 4.5±2.275** | 6.255±2.072** |

* $P < 0/05$ ** $p < 0.001$

Table 5. Correlation between glycated haemoglobin and lipid parameters and glucose

| Groups | | TG | HDL | LDL | TC | Glucose |
|-----------|---------|----------|----------|----------|----------|----------|
| Group I | r | 0.20908 | 0.360826 | 0.133325 | 0.07368 | 0.152485 |
| | p value | 0.3765 | 0.1124 | 0.5760 | 0.7521 | 0.5220 |
| Group II | r | -0.11597 | -0.16323 | 0.2865 | 0.2284 | 0.337888 |
| | p value | 0.6265 | 0.4920 | 0.2207 | 0.3333 | 0.1452 |
| Group III | r | 0.031536 | -0.3585 | 0.2468 | 0.275519 | 0.415772 |
| | p value | 0.8952 | 0.1206 | 0.2941 | 0.2390 | 0.0680 |

concentration, low HDL cholesterol concentration and increased concentration of LDL-cholesterol. The lipid changes associated with diabetes mellitus are attributed to increased free fatty acid flux secondary to insulin resistance [14].

The relationship between the typical lipid profile exhibited by patients with type 2 diabetes and risk of cardiovascular disease are also proved [15]. Hemoglobin A1c provides a tool for blood sugar monitoring in persons with diabetes; chronic hyperglycemia is related to the development of micro vascular disease, and also represents correlation between glycated

hemoglobin and serum lipids in diabetic patients.[16]

In the present study, the pattern of lipid profile in type 2 diabetic patients and its correlation with HbA1c is studied. Earlier studies have shown that high level of cholesterol, triglyceride, LDL and low HDL in type 2 diabetics are well known risk factors for cardiovascular disease. Insulin resistance and hyperglycemia promote atherosclerosis at the arterial wall with the help of macrophages and endothelial cells results in plaque formation. At the same time hyperglycemia acts synergistically with other

cardio vascular risk factors [17]. The cause of dyslipidemia in type 2 diabetes mellitus may be due to the resistance of the insulin action which in turn influences the liver apo-lipoprotein production. The direct correlation between FBS and HbA1c with total cholesterol (TC), triglycerides (TG) and LDL and inverse correlation with HDL are also well postulated [18].

Inflammatory markers such as IL-1, IL-6, IL-15, and TNF- α were found to be low in type 2 diabetes patients, but the levels of IL-10, IFN- γ , and caspase-1 were high, compared to normal controls. Type 2 diabetes patients with hypertension show significantly decreased levels of IL-1 and caspase-1 compared to patients without hypertension [19].

There is risk of colorectal cancer is more in diabetes because of their sharing environmental factors such as obesity, sedentary life style and high fat diet. Excess insulin levels were shown in animals to stimulate IGF-1 which is also a risk factor for colorectal cancer [20].

In the current study, the levels of glycated hemoglobin in diabetic groups (II and III) were found to be highly significant in comparison to control group. The study also revealed that there is an increase in the cholesterol levels in group III diabetic patients with cardiovascular complications when compared to the control group. Such significance was not found between the control group and the uncomplicated diabetic group II. Group III showed significant increase in LDL-cholesterol in comparison to the control group (group I) and uncomplicated diabetic group (group II).

The HDL-cholesterol values were significantly lower in both uncomplicated and complicated groups (II and III) when compared to the control group. There was also significant decrease in HDL-cholesterol in complicated group when compared to uncomplicated diabetic group. Lipoprotein lipase is the key enzyme in the metabolism of triglyceride rich lipoproteins. LPL in the pre heparin serum mass reflects the insulin sensitivity of diabetic patients receiving neither insulin nor hypoglycemic agents. [21], low pre heparin LPL mass may be deeply involved in the progression of coronary atherosclerosis [22]. Significant high concentration of triglycerides was found in uncomplicated and complicated groups (II and III). There was significant rise in all the lipid profiles in diabetic patients with

cardiovascular complication as compared to the controls and also diabetics with no recognized complications. Thus, this study suggests association of serum lipids and glycated hemoglobin with complications in type 2 diabetes. In another study, significant correlations between HbA1c with TC, LDL and LDL/HDL ratio were observed [23]. In a study, HbA1c demonstrated significant positive relationship with TC, TG, HDL and LDL [24]. A significantly higher cardiovascular disease (CVD) in persons with high levels of HbA1c is also reported [25]. HbA1c can predict serum lipid levels in both male and female diabetic patients and is a marker routinely used for long-term glycemic control and they observed a direct and significant correlation between HbA1c with TC, TG and LDL, and reverse correlation with HDL [26,27].

5. CONCLUSION

Type 2 diabetes mellitus continues to be a serious health concern in the growing world. Cardiovascular events in type 2 diabetes mellitus patients is an important complication that requires immediate attention. Studies have shown that an increase in glycated hemoglobin and abnormal lipid profile is prevalent in diabetic patients. The current study concluded that there is a definite positive correlation of glycated hemoglobin with the levels of total cholesterol, triglyceride, and low density lipoprotein cholesterol. This strongly suggests dyslipidemia in diabetic patients when not under optimal control.

CONSENT

Not applicable since this is an observational study.

DISCLAIMER

This manuscript was presented in the conference "American Association of Clinical Chemistry, Annual Meeting 2014 and Clinical Lab Expo, at Chicago, USA" available link is "http://www.researchgate.net/publication/262840903_CORRELATION_BETWEEN_GLYCATED_HEMOGLOBIN_AND_SERUM_LIPIDS_IN_TYPE_2_DIABETICS_IN_EASTERN_LIBYA".

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 2009;32(1):S62–S67.
2. Dimitrios AS, Dara PS, Sparkset EA, et al. Association between glycosylated hemoglobin, left ventricular mass and aortic function in nondiabetic individuals with insulin resistance. *Eur J Endocrinol*. 2007;157(1):63-8.
3. Diagnosis and classification of diabetes mellitus: *Diabetes Care*. 2010;33(1).
4. Massi-Benedetti M. Changing targets in the treatment of type 2 diabetes. *Curr Med Res Opin*. 2006;2(22):S5-13.
5. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. *Diabetologia*. 2007;50:2239-2244.
6. Masram SW, Bimanpalli MV, Ghangle S. Study of Lipid Profile and glycated hemoglobin in diabetes mellitus. *Indian Medical Gazette*. 2012;257-265.
7. Tietz NW. *Clinical guide to laboratory tests*, 3rd Edition. WB. Saunders Co. Philadelphia. 1995;287.
8. Jeppson JO, Kobold U, Barr J, et al. Approved IFCC reference method for measurement of HbA1c in human blood. *Clin Chem Lab Med*. 2007;45:1077-1080.
9. Grove T. Effect of reagent pH on determination of HDL cholesterol by precipitation with sodium Phosphotungstate-magnesium. *Chlin. Chem*. 1997;25–560.
10. Naito H. Disorder of lipid metabolism In: Kaplan LA, pesce AJ, Eds. *Clinical chemistry, theory, analysis and correlation*. St. Louis: Mosby Company. 1984;550-593.
11. Nalto K. High density lipoprotein (HDL) cholesterol. *Clin. Chem. The C.V. Mosty Co. St Louls. Toronto. Princeton*. 1984; 1207, 1213 and 37.
12. Young D. *Effects of drugs on clinical Laboratory tests*. 3rd edition. 1990;3:6-12.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499-502.
14. Arshag D Mooradian. Dyslipidemia in type 2 diabetes mellitus. *Nature Clinical Practice Endocrinology & Metabolism*. 2009;50:150-159.
15. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. *Med Clin N Am*. 2004;88:897–909.
16. Rafael Carmena. High risk of lipoprotein dysfunction in Type 2 diabetes mellitus. *Rev Esp Cardiol*. 2008;8(Supl C):18-24.
17. Karin E. Bornfeldt¹, Ira Tabas². Insulin Resistance, Hyperglycemia, and Atherosclerosis, *Cell metabolism*. 2011; 14(5):575–585.
18. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidemia. *Clin Exp Med*. 2007;7(1):24-9.
19. Ahmed Al-Shukaili, Saif AL-Ghafri, Safia Al-Marhoobi, Said Al-Abri, Jawad Al-Lawati, Masoud Al-Maskari. Analysis of inflammatory mediators in type 2 diabetes patients. *International Journal of Endocrinology*. 2013(2013):7. Article ID 976810.
20. Nancy Volkens. Diabetes and cancer scientists search for a possible link. *JNCI J Natl Cancer Inst*. 2000;92(3):192-194.
21. Hanyu O, et al. Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents. *Clin Chim Acta*. 2007;384:118-123.
22. Hitsumoto T, et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. *Atherosclerosis*. 2000;153: 391-396.
23. Vinod Mahato R, Gyawali P, Raut PP, Regmi P, Singh DRP, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. *Biomedical Research*. 2011;229(3):375-80.
24. Friedewald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical Chemistry*. 1972;18(6):499-502.
25. Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N. Relationship between HbA1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: Sub-analysis of a large-scale randomized controlled trial. *Cardiovascular Diabetology*. 2011;10:58.

26. Ahmad Khan H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. *Acta Diabetol.* 2007;44(4):193-200.
27. Arivarasan A, Rana G, Sharma A, Kumar M, Jhang K, Chakraborty A, et al. Clinical management of lipid profile, renal and liver function versus HbA1c profile in diabetes affected patients of Vellore, Tamil Nadu, India. *African Journal of Pharmacy and Pharmacology.* 2012;6(40):2832-6.

© 2016 Naseb et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://sciencedomain.org/review-history/11608>